# Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

> **NCT05412472** · PHASE1 · COMPLETED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** GC4419

## Key facts

- **NCT ID:** NCT05412472
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-04-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412472, "Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05412472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*